Nomura expects that the group's sales in the third quarter of this year will increase by 35% year-on-year to 0.47 billion RMB, with a net loss of 0.425 billion RMB, reflecting that sales are increasing as planned.
Zhixun Finance APP learned that Nomura released research reports stating that the target price of Remegen (09995) was raised by 8%, from HK$15.12 to HK$16.37, maintaining a "neutral" rating, believing that the company may need to further control its operating expenses.
The report stated that Nomura raised its net loss forecast for Remegen for the next two years by 1.3% and 8%, respectively, to reflect the sales increase of its two listed products, RC18 and RC48, and the increase in interest expenses due to the group's cash burn condition. The bank expects that the group's sales in the third quarter of this year will increase by 35% year-on-year to 0.47 billion RMB, with a net loss of 0.425 billion RMB, reflecting that sales are increasing as planned.
